Loading...
Docoh
Log in Free sign up

Abeona Therapeutics (ABEO)

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.

Company profile

Ticker
ABEO
Exchange
NASDAQ
Website
abeonatherapeutics.com
CEO
Joao Siffert
Employees
Incorporated
Delaware
Location
New York
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
ACCESS PHARMACEUTICALS INC, CHEMEX PHARMACEUTICALS INC, PLASMATECH BIOPHARMACEUTICALS INC
SEC CIK
0000318306
Corporate docs
Subsidiaries
Abeona Therapeutics LLC • Abeona Therapeutics Europe, S.L. • MacroChem Corporation • Virium Pharmaceuticals, Inc. ...
IRS number
830221517

ABEO stock data

News

From Benzinga Pro
SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $5
11 Aug 22
SVB Leerink analyst Mani Foroohar maintains Abeona Therapeutics (NASDAQ:ABEO) with a Market Perform and raises the price target from $1 to $5.
Recap: Abeona Therapeutics Q2 Earnings
11 Aug 22
Abeona Therapeutics (NASDAQ:ABEO) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Abeona Therapeutics Q2 EPS $(2.08) Up From $(4.00) YoY
11 Aug 22
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(2.08) per share. This is a 48 percent increase over losses of $(4.00) per share from the same period last year.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 Aug 22
Abeona Therapeutics Regains Compliance With Nasdaq Listing Requirements
20 Jul 22

Press releases

From Benzinga Pro
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug 22
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
20 Jul 22
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
6 Jun 22
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
19 May 22
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
17 May 22

Analyst ratings and price targets

Last 3 months
SVB Leerink
Maintains
Market Perform
$5.00
11 Aug 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
12 Aug 22
31 Dec 22

Financial summary

Financial statements Chart ABEO financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 12.02M 12.02M 12.02M 12.02M 12.02M 12.02M
Cash burn (monthly) 4.73M 1.34M 2.67M 7.51M 3M 5.27M
Cash used (since last report) 6.77M 1.92M 3.82M 10.75M 4.3M 7.55M
Cash remaining 5.25M 10.1M 8.2M 1.27M 7.72M 4.47M
Runway (months of cash) 1.1 7.5 3.1 0.2 2.6 0.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

ABEO insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jul 22 Vazzano Joseph Walter Common stock Grant Acquire A No No 0 12,000 0 20,000
15 Jun 22 Mark Alvino Common Stock Sell Dispose S No No 0.1549 20,000 3.1K 27,181
6 Jun 22 Mark Alvino Common Stock Sell Dispose S No No 0.1561 35,000 5.46K 47,181
1 Jun 22 Vishwas Seshadri Common Stock Payment of exercise Dispose F No No 0.16 81,525 13.04K 268,475
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ABEO institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Soligenix • Jazz Pharmaceuticals • Alder Biopharmaceuticals • Synedgen • Galera Therapeutics • uniQure • Regenxbio • Voyager Therapeutics • 4D Molecular Therapeutics • Editas Medicine

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: assume, assumption, ASU, bid, combined, confirming, constraint, consummated, curtail, cut, distribution, doubt, effectuate, embedded, enhanced, entity, escrow, FASB, fourth, fraction, fractional, half, higher, hinder, holder, implement, individually, instrument, issuable, issuance, longer, multiplied, notification, occurrence, ophthalmology, passed, pertaining, Pharmaceutical, premium, proportional, Proportionate, proportionately, prove, purpose, redemption, refund, reimburse, reimbursement, reserved, retroactively, Rett, Rule, Secretary, sooner, stockholder, subsequent, subsequently, Subtopic, summary, tiered, transition, Ultragenyx, underwent, underwriting, underwritten, upfront, vendor, voucher, warrant, wrong
Removed: accessing, adverse, April, calculate, carry, contract, dilution, expenditure, favor, hand, IIIB, lack, loan, marketable, summarized
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
10-Q
2021 Q2
Quarterly report
28 Jul 21
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
24 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
Current reports
View all
8-K
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug 22
8-K
Other Events
20 Jul 22
8-K
Material Modifications to Rights of Security Holders
30 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
8-K
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
19 May 22
8-K
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
17 May 22
8-K
Abeona Therapeutics Reports First Quarter 2022 Financial Results
13 May 22
8-K
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
2 May 22
8-K
Amendments to Articles of Incorporation or Bylaws
28 Apr 22
8-K
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
31 Mar 22
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
19 Jul 22
424B5
Prospectus supplement for primary offering
17 Dec 21
424B5
Prospectus supplement for primary offering
16 Dec 21
424B5
Prospectus supplement for primary offering
19 Nov 21
S-3/A
Shelf registration (amended)
19 Oct 21
S-3/A
Shelf registration (amended)
26 Aug 21
S-3
Shelf registration
7 Jun 21
S-8
Registration of securities for employees
21 May 20
424B5
Prospectus supplement for primary offering
23 Dec 19
25-NSE
Exchange delisting
20 Dec 19
Proxies
View all
DEFA14A
Additional proxy soliciting materials
4 Aug 22
DEF 14A
Definitive proxy
11 Jul 22
DEF 14A
Definitive proxy
12 May 22
PRE 14A
Preliminary proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
12 May 21
DEFR14A
Revised proxy
19 Apr 21
DEF 14A
Definitive proxy
9 Apr 21
PRE 14A
Preliminary proxy
30 Mar 21
PX14A6G
Letter to shareholders
29 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 20
Other
View all
EFFECT
Notice of effectiveness
25 Oct 21
CORRESP
Correspondence with SEC
18 Oct 21
CORRESP
Correspondence with SEC
29 Aug 21
CORRESP
Correspondence with SEC
26 Aug 21
UPLOAD
Letter from SEC
10 Jun 21
UPLOAD
Letter from SEC
23 Sep 19
CORRESP
Correspondence with SEC
19 Sep 19
UPLOAD
Letter from SEC
17 Sep 19
CORRESP
Correspondence with SEC
19 Aug 19
UPLOAD
Letter from SEC
5 Aug 19
Ownership
View all
4
ABEONA THERAPEUTICS / Joseph Walter Vazzano ownership change
25 Jul 22
4
ABEONA THERAPEUTICS / Mark Alvino ownership change
17 Jun 22
4
ABEONA THERAPEUTICS / Vishwas Seshadri ownership change
17 Jun 22
4
ABEONA THERAPEUTICS / Mark Alvino ownership change
7 Jun 22
4
ABEONA THERAPEUTICS / Joseph Walter Vazzano ownership change
16 Mar 22
3
ABEONA THERAPEUTICS / Joseph Walter Vazzano ownership change
16 Mar 22
SC 13G/A
ABEONA THERAPEUTICS / ADAGE CAPITAL PARTNERS GP, L.L.C. ownership change
9 Feb 22
4
ABEONA THERAPEUTICS / Brendan M. O'Malley ownership change
8 Dec 21
4
ABEONA THERAPEUTICS / Brendan M. O'Malley ownership change
5 Nov 21
4
ABEONA THERAPEUTICS / Vishwas Seshadri ownership change
18 Oct 21

Patents

Utility
Intrathecal and Intravenous Combination Gene Therapy for the Treatment of Infantile Batten Disease
23 Jun 22
Methods for treating IBD or an IBD related disorder in a subject in need thereof are provided that comprise combined intrathecal administration of a polynucleotide comprising a CLN1 open reading frame and intravenous administration of the polynucleotide.
Utility
Recombinant Adeno-associated Viral Vector for Gene Delivery
24 Mar 22
Provided herein are recombinant AAV vectors, AAV viral vectors, and capsid proteins for improved gene therapy, and methods for their manufacture and use.

Transcripts

View all
2022 Q1
Earnings call transcript
17 May 22
2021 Q1
Earnings call transcript
25 May 21
2020 Q4
Earnings call transcript
25 Mar 21
2019 Q2
Earnings call transcript
12 Aug 19
2019 Q1
Earnings call transcript
14 May 19
2018 Q4
Earnings call transcript
19 Mar 19
2018 Q3
Earnings call transcript
12 Nov 18
2018 Q2
Earnings call transcript
10 Aug 18
2018 Q1
Earnings call transcript
14 May 18
2017 Q4
Earnings call transcript
27 Mar 18

Reddit threads

View all